More than 30 million Americans suffer from diabetes—one of several chronic medical conditions accounting for an overall increased demand for health services as well as increased costs for medical care. Unfortunately, the solutions to chronic conditions are complex, and there is no one simple solution. New innovative treatments and advanced therapies as well as a faster route for generics to be approved by the Food and Drug Administration offer some hope. And coupled with aggressive prevention and wellness practices, there can be additional improvements that include controlled costs and improved outcomes. Read More
From petrochemicals to metals and even world-class food products that consumers around the world enjoy, Louisiana manufacturers with a special process or “secret sauce” make up the core of the state’s innovators. Manufacturers, in particular, account for more than three-quarters of all private-sector research and development (R&D) in the United States. R&D is critical to their success and the countless other Louisiana enterprises that rely on them. And in an extremely competitive global economy, if a company isn’t innovating, it’s falling behind. Read More
Manufacturers in the United States know that innovation and intellectual property (IP) are crucial for their economic success and that their competitiveness depends on continual innovation: creation of new products, technologies and more efficient processes that meet customer needs. While the United States provides strong IP protections and enforcement, that is too often not the case in overseas markets where IP theft and infringement jeopardizes the innovation and competitiveness of manufacturers in the United States, costing jobs and economic growth here at home. Read More
Manufacturers in the United States perform more than three-quarters of all private-sector research and development (R&D), driving more innovation than any other sector. R&D is the key to innovation and medical discovery, but developing any new product is a very risky, lengthy and expensive process. Read More
From automobile and steel production to print and publishing services, Maryland manufacturers and other research-based companies today serve as global innovators. Manufacturers in particular account for more than three-quarters of all private-sector research and development (R&D) in the United States. R&D is critical to both their success and the countless other Maryland enterprises that rely on them. And in an extremely competitive global economy, if a company isn’t innovating, it’s falling behind. Read More
The National Association of Manufacturers (NAM) yesterday urged the U.S. government to boost its efforts to protect U.S. manufacturing innovation against the threat of intellectual property (IP) theft globally in a detailed submission to the Office of the U.S. Trade Representative (USTR). Innovation and IP remains the foundation for a globally competitive manufacturing sector in the United States. Yet, global infringement of IP, including patents, trade secrets, trademarks and copyrights, hurts the ability of manufacturers in the United States to not only innovate but also to sustain and create well-paying jobs. The NAM looks forward to working closely with the Trump administration on stepped-up and vigorous efforts to combat IP theft and to protect and secure strong enforcement of IP rights both at home and abroad. Read More
Montana manufacturers, technology companies and other research-based operations are global innovators. Manufacturers in particular account for more than three-quarters of all private-sector research and development (R&D) in the United States. R&D is critical to the success of the countless Montana enterprises that rely on innovation. And in an extremely competitive global economy, if a company isn’t innovating, it’s falling behind.
This is especially true for biopharmaceutical manufacturers creating new medicines for patients and animals. However, the price of manufacturing a new medicine is extremely costly and risky. On average, it takes a decade to bring a new patient medicine through the entire R&D process and into the marketplace, and only about 12 percent of the medicines that enter the process are actually approved by the Food and Drug Administration. Therefore, it is absolutely critical that manufacturers’ R&D and proprietary information are not compromised.
Unfortunately, “transparency” legislation was recently introduced in Montana that would force biopharmaceutical manufacturers to turn over highly confidential information and proprietary data related to R&D as well as sales and marketing costs. This approach would have damaging effects and would not reduce health care costs. Requiring manufacturers to publicly reveal a breakdown of specific costs and information related to trade secrets would in no way benefit consumers and could impede competition, which would drive up costs.
The time, effort and costs associated with bringing new medicines or products to market must be acknowledged and valued. While this specific bill is targeted at manufacturers of medicine, it sets an alarming precedent for manufacturers across all industries. In short, it’s a slippery slope for all industries once established. Any legislation that jeopardizes manufacturers’ highly confidential information and deters innovators from innovating is a threat to consumers, manufacturing jobs and the state’s economy.
The manufacturing industry employs more than 18,700 Montanans in high-skilled and high-wage jobs. Policymakers in Montana and at the federal level should work to create policies that help innovators attract and retain investment. The NAM opposes any efforts that would invalidate longstanding intellectual property and trade secrets protections and force manufacturers of medicines to heed new government-driven demands that are contrary to basic free market principles.
During the current debate on legislation to repeal Obamacare, the Senate may have the opportunity to vote on a provision—introduced by Sen. Al Franken (D-MN)—that would eliminate the ability of companies to deduct advertising and promotional expenses related to prescription drugs. This is a misguided idea, and we urge senators to reject this proposal. Long recognized as a legitimate and necessary business expense, advertising plays a critical role in the competitiveness of manufacturers and the success of their products. Advertising plays a central role in driving market growth and innovation, which benefits both the manufacturer and the consumer. In doing so, advertising also helps drive prices down by spurring competition. In contrast, disallowing a deduction for direct-to-consumer advertising of prescription drugs increases the costs to pharmaceutical companies by denying a legitimate business expense and also unfairly targets a specific industry for discriminatory tax treatment.
Sens. Deb Fischer (R-NE), Cory Gardner (R-CO), Cory Booker (D-NJ) and Brian Schatz (D-HI) introduced the NAM-supported Developing Innovation and Growing the Internet of Things (DIGIT) Act today. This legislation creates a strategic partnership between manufacturers and the public sector focused on fostering the growth of the Internet of Things (IoT). The National Association of Manufacturers looks forward to working with both the House and Senate to move this bipartisan bill. Read More
In the final hours before Congress went home for the holidays, it passed a bill that places a priority on innovation and the important role basic research plays in today’s manufacturing economy. The House and Senate both unanimously passed S. 3084, the American Innovation and Competitiveness Act.